Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
Palvella Therapeutics (NASDAQ:PVLA), a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases, will host its Q2 2025 financial results conference call on August 14, 2025, at 8:30 a.m. ET.
The company, which focuses on developing treatments for conditions with no current FDA-approved therapies, will provide both financial results and a corporate update during the call. Investors can access the live webcast with slides through Palvella's website under the "Events & Presentations" section, with a replay available for 90 days after the call.
Palvella Therapeutics (NASDAQ:PVLA), una societ脿 biofarmaceutica in fase clinica che sviluppa terapie per malattie genetiche rare della pelle, terr脿 la sua conferenza telefonica sui risultati finanziari del secondo trimestre 2025 il 14 agosto 2025 alle 8:30 ET.
La societ脿, che si concentra sullo sviluppo di trattamenti per condizioni senza terapie approvate dalla FDA, fornir脿 durante la chiamata sia i risultati finanziari sia un aggiornamento aziendale. Gli investitori potranno seguire la diretta webcast con le slide sul sito web di Palvella nella sezione "Eventi e Presentazioni", con una replica disponibile per 90 giorni dopo la chiamata.
Palvella Therapeutics (NASDAQ:PVLA), una empresa biofarmac茅utica en etapa cl铆nica que desarrolla terapias para enfermedades gen茅ticas raras de la piel, realizar谩 su conferencia telef贸nica de resultados financieros del segundo trimestre de 2025 el 14 de agosto de 2025 a las 8:30 a.m. ET.
La compa帽铆a, que se enfoca en desarrollar tratamientos para condiciones sin terapias aprobadas por la FDA, ofrecer谩 durante la llamada tanto los resultados financieros como una actualizaci贸n corporativa. Los inversores podr谩n acceder a la transmisi贸n en vivo con diapositivas a trav茅s del sitio web de Palvella en la secci贸n "Eventos y Presentaciones", con una repetici贸n disponible durante 90 d铆as despu茅s de la llamada.
Palvella Therapeutics (NASDAQ:PVLA)電� 頋穩 鞙犾爠靹� 頂茧秬 歆堩櫂 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 8鞗� 14鞚� 鞓れ爠 8鞁� 30攵�(霃欕秬鞁滉皠)鞐� 2025雲� 2攵勱赴 鞛 鞁れ爜 旎嵓霟办姢 旖�鞚� 臧滌禍頃� 鞓堨爼鞛呺媹雼�.
FDA 鞀轨澑鞚� 鞐嗠姅 歆堩櫂 旃橂鞝� 臧滊皽鞐� 歆戩頃橂姅 鞚� 須岇偓電� 旖滌棎靹� 鞛 鞁れ爜瓿� 須岇偓 順勴櫓 鞐呺嵃鞚错姼毳� 鞝滉车頃� 瓴冹瀰雼堧嫟. 韴瀽鞛愲摛鞚� Palvella 鞗轨偓鞚错姼鞚� "鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴" 靹轨厴鞚� 韱淀暣 鞀澕鞚措摐鞕� 頃粯 霛检澊敫� 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃� 靾� 鞛堨溂氅�, 旖� 膦呺 頉� 90鞚� 霃欖晥 雼れ嫓氤搓赴 靹滊箘鞀るゼ 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Palvella Therapeutics (NASDAQ:PVLA), une soci茅t茅 biopharmaceutique en phase clinique d茅veloppant des th茅rapies pour des maladies g茅n茅tiques rares de la peau, organisera sa conf茅rence t茅l茅phonique sur les r茅sultats financiers du deuxi猫me trimestre 2025 le 14 ao没t 2025 脿 8h30 ET.
L'entreprise, qui se concentre sur le d茅veloppement de traitements pour des affections sans th茅rapies approuv茅es par la FDA, pr茅sentera lors de l'appel 脿 la fois les r茅sultats financiers et une mise 脿 jour d'entreprise. Les investisseurs pourront acc茅der 脿 la diffusion en direct avec les diapositives via le site web de Palvella dans la section 芦 脡v茅nements & Pr茅sentations 禄, avec un replay disponible pendant 90 jours apr猫s l'appel.
Palvella Therapeutics (NASDAQ:PVLA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Therapien f眉r seltene genetische Hautkrankheiten entwickelt, wird seine Finanzergebnisse f眉r das zweite Quartal 2025 am 14. August 2025 um 8:30 Uhr ET in einer Telefonkonferenz vorstellen.
Das Unternehmen, das sich auf die Entwicklung von Behandlungen f眉r Erkrankungen ohne derzeit von der FDA zugelassene Therapien spezialisiert hat, wird w盲hrend des Anrufs sowohl finanzielle Ergebnisse als auch ein Unternehmensupdate pr盲sentieren. Investoren k枚nnen den Live-Webcast mit Folien 眉ber die Website von Palvella im Bereich "Events & Presentations" verfolgen; eine Aufzeichnung ist 90 Tage nach dem Anruf verf眉gbar.
- None.
- None.
WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)听聽(Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025.
Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, August 14, 2025, to discuss financial results and provide a corporate update.
To access the live webcast of the call with slides, please click or visit the "Events & Presentations" section of Palvella鈥檚 website. To access the call by phone, please use this , and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company鈥檚 website at .
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN鈩� platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella鈥檚 lead product candidate, QTORIN
QTORIN鈩� rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.
颁辞苍迟补肠迟听滨苍蹿辞谤尘补迟颈辞苍
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
FAQ
When is Palvella Therapeutics (PVLA) Q2 2025 earnings call?
How can I access Palvella Therapeutics (PVLA) Q2 2025 earnings call?
What does Palvella Therapeutics (PVLA) specialize in?
How long will Palvella Therapeutics (PVLA) Q2 2025 earnings call replay be available?
